Triumvira is a clinical-stage immuno-oncology company focused on developing targeted autologous and allogeneic T cell therapeutics. Leveraging T cell biology, Triumvira aims to treat a broad range of cancers. Backed by a strong intellectual property portfolio, the company is led by a team with expertise in cell therapy, oncology drug development, and manufacturing. Utilizing cutting-edge technologies, Triumvira is advancing TAC-based programs for innovative cancer treatments.